Connect your AI

Candel Therapeutics, Inc. CADL Price / book

Price / book at other companies

Bristol-Myers SquibbBMY

6.2×-1.0×

AmgenAMGN

20.6×-6.3×

Gilead SciencesGILD

7.4×+0.1×

Replimune GroupREPL

3.6×+1.7×

CG OncologyCGON

5.2×+2.6×

Immix Biopharma, Inc.IMMX

5.7×+0.9×

Other financials

Income statement

Revenue$31.0K0.0%

Operating income-$16.3M-100%

Net income-$8.9M-220%

EPS (diluted)-$0.14-208%

Balance sheet

Cash & equivalents$194.8M+111%

Total debt$2.8M-73.9%

Total equity$138.0M+84.8%

Total assets$201.9M+111%

Cash flow

Operating cash flow-$18.0M-109%

CapEx$675.0K+22,400%

Free cash flow-$18.7M-117%

Valuation

Market cap$693.87M+192%

Enterprise value$501.88M+220%

P/S5,595.7×-18,674×

Profitability

Operating margin-28,000.8%+15,050pp

Net margin-15,156.5%-5,064pp

FCF margin-26,383.9%+14,851pp

Returns & leverage

Return on equity-51.2%-16.6pp

Debt / equity0×-0.1×

Current ratio28×+23.4×

Where this comes from

Calculated from Candel Therapeutics, Inc.’s reported figures.

market cap/total stockholders equity=2.6×

Based on the most recent quarter.

The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Candel Therapeutics, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Candel Therapeutics, Inc.'s price / book?: Candel Therapeutics, Inc. (CADL) reported price / book of 2.6× in Q1 2026.
How has Candel Therapeutics, Inc.'s price / book changed year-over-year?: Candel Therapeutics, Inc.'s price / book decreased by 27.2% year-over-year, from 3.6× to 2.6×.
What is the long-term trend for Candel Therapeutics, Inc.'s price / book?: Over 4 years (2021 to 2025), Candel Therapeutics, Inc.'s price / book has grown at a 14.3% compound annual growth rate (CAGR), from 3.5× to 6×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.